In the lipid clinic setting, in patients you have treated with PCSK9 inhibitors, what are you finding as far as regimen adherence, toleration, and patient engagement/satisfaction with these injectable strategies?

Name: In the lipid clinic setting, in patients you have treated with PCSK9 inhibitors, what are you finding as far as regimen adherence, toleration, and patient engagement/satisfaction with these injectable strategies?
Uploaded: 2019-03-11T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Professor of Medicine Division of Endocrinology, Metabolism & Lipid Research Washington University in St. Louis St. Louis, MO